Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications

A. Avenoso, E. Spina, G. Campo, G. Facciola, Marcella Ferlito, P. Zuccaro, E. Perucca, A. P. Caputi

Research output: Contribution to journalArticle

Abstract

The extent and clinical significance of the pharmacokinetic interaction between fluoxetine and haloperidol was studied in 13 schizophrenic patients with prominent negative symptoms. Patients stabilized on chronic low-dose haloperidol (3-8 mg day-1) received additional fluoxetine (20 mg day-1) for 12 consecutive weeks. Mean plasma concentrations of haloperidol increased significantly from 6.5 ± 2.4 nmol l-1 at baseline to 8.8 ± 3.6 nmol l-1 (P <0.01) at week 12 of fluoxetine treatment, but this effect was not associated with an increase in mean extrapyramidal side effects score on the Simpson and Angus Scale. The improvement in negative symptomatology, as measured by the Scale for Assessment of Negative Symptoms, did not correlate significantly with the increase in plasma haloperidol levels. Though our findings confirm that fluoxetine impairs haloperidol clearance, this interaction is unlikely to have adverse clinical consequences, at least in patients chronically stabilized on a low dosage of haloperidol. As fluoxetine is a potent inhibitor of cytochrome P450 (CYP) 2D6, these results also provide indirect evidence for an involvement of CYP2D6 in the metabolism of haloperidol.

Original languageEnglish (US)
Pages (from-to)335-339
Number of pages5
JournalPharmacological Research
Volume35
Issue number4
StatePublished - 1997
Externally publishedYes

Fingerprint

Fluoxetine
Haloperidol
Pharmacokinetics
Cytochrome P-450 CYP2D6
Symptom Assessment

Keywords

  • CYP2D6
  • Drug interaction
  • Fluoxetine
  • Haloperidol
  • Negative symptoms
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Avenoso, A., Spina, E., Campo, G., Facciola, G., Ferlito, M., Zuccaro, P., ... Caputi, A. P. (1997). Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications. Pharmacological Research, 35(4), 335-339.

Interaction between fluoxetine and haloperidol : Pharmacokinetic and clinical implications. / Avenoso, A.; Spina, E.; Campo, G.; Facciola, G.; Ferlito, Marcella; Zuccaro, P.; Perucca, E.; Caputi, A. P.

In: Pharmacological Research, Vol. 35, No. 4, 1997, p. 335-339.

Research output: Contribution to journalArticle

Avenoso, A, Spina, E, Campo, G, Facciola, G, Ferlito, M, Zuccaro, P, Perucca, E & Caputi, AP 1997, 'Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications', Pharmacological Research, vol. 35, no. 4, pp. 335-339.
Avenoso A, Spina E, Campo G, Facciola G, Ferlito M, Zuccaro P et al. Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications. Pharmacological Research. 1997;35(4):335-339.
Avenoso, A. ; Spina, E. ; Campo, G. ; Facciola, G. ; Ferlito, Marcella ; Zuccaro, P. ; Perucca, E. ; Caputi, A. P. / Interaction between fluoxetine and haloperidol : Pharmacokinetic and clinical implications. In: Pharmacological Research. 1997 ; Vol. 35, No. 4. pp. 335-339.
@article{985f7a6f598f436bb743f1ba7becb726,
title = "Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications",
abstract = "The extent and clinical significance of the pharmacokinetic interaction between fluoxetine and haloperidol was studied in 13 schizophrenic patients with prominent negative symptoms. Patients stabilized on chronic low-dose haloperidol (3-8 mg day-1) received additional fluoxetine (20 mg day-1) for 12 consecutive weeks. Mean plasma concentrations of haloperidol increased significantly from 6.5 ± 2.4 nmol l-1 at baseline to 8.8 ± 3.6 nmol l-1 (P <0.01) at week 12 of fluoxetine treatment, but this effect was not associated with an increase in mean extrapyramidal side effects score on the Simpson and Angus Scale. The improvement in negative symptomatology, as measured by the Scale for Assessment of Negative Symptoms, did not correlate significantly with the increase in plasma haloperidol levels. Though our findings confirm that fluoxetine impairs haloperidol clearance, this interaction is unlikely to have adverse clinical consequences, at least in patients chronically stabilized on a low dosage of haloperidol. As fluoxetine is a potent inhibitor of cytochrome P450 (CYP) 2D6, these results also provide indirect evidence for an involvement of CYP2D6 in the metabolism of haloperidol.",
keywords = "CYP2D6, Drug interaction, Fluoxetine, Haloperidol, Negative symptoms, Schizophrenia",
author = "A. Avenoso and E. Spina and G. Campo and G. Facciola and Marcella Ferlito and P. Zuccaro and E. Perucca and Caputi, {A. P.}",
year = "1997",
language = "English (US)",
volume = "35",
pages = "335--339",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Interaction between fluoxetine and haloperidol

T2 - Pharmacokinetic and clinical implications

AU - Avenoso, A.

AU - Spina, E.

AU - Campo, G.

AU - Facciola, G.

AU - Ferlito, Marcella

AU - Zuccaro, P.

AU - Perucca, E.

AU - Caputi, A. P.

PY - 1997

Y1 - 1997

N2 - The extent and clinical significance of the pharmacokinetic interaction between fluoxetine and haloperidol was studied in 13 schizophrenic patients with prominent negative symptoms. Patients stabilized on chronic low-dose haloperidol (3-8 mg day-1) received additional fluoxetine (20 mg day-1) for 12 consecutive weeks. Mean plasma concentrations of haloperidol increased significantly from 6.5 ± 2.4 nmol l-1 at baseline to 8.8 ± 3.6 nmol l-1 (P <0.01) at week 12 of fluoxetine treatment, but this effect was not associated with an increase in mean extrapyramidal side effects score on the Simpson and Angus Scale. The improvement in negative symptomatology, as measured by the Scale for Assessment of Negative Symptoms, did not correlate significantly with the increase in plasma haloperidol levels. Though our findings confirm that fluoxetine impairs haloperidol clearance, this interaction is unlikely to have adverse clinical consequences, at least in patients chronically stabilized on a low dosage of haloperidol. As fluoxetine is a potent inhibitor of cytochrome P450 (CYP) 2D6, these results also provide indirect evidence for an involvement of CYP2D6 in the metabolism of haloperidol.

AB - The extent and clinical significance of the pharmacokinetic interaction between fluoxetine and haloperidol was studied in 13 schizophrenic patients with prominent negative symptoms. Patients stabilized on chronic low-dose haloperidol (3-8 mg day-1) received additional fluoxetine (20 mg day-1) for 12 consecutive weeks. Mean plasma concentrations of haloperidol increased significantly from 6.5 ± 2.4 nmol l-1 at baseline to 8.8 ± 3.6 nmol l-1 (P <0.01) at week 12 of fluoxetine treatment, but this effect was not associated with an increase in mean extrapyramidal side effects score on the Simpson and Angus Scale. The improvement in negative symptomatology, as measured by the Scale for Assessment of Negative Symptoms, did not correlate significantly with the increase in plasma haloperidol levels. Though our findings confirm that fluoxetine impairs haloperidol clearance, this interaction is unlikely to have adverse clinical consequences, at least in patients chronically stabilized on a low dosage of haloperidol. As fluoxetine is a potent inhibitor of cytochrome P450 (CYP) 2D6, these results also provide indirect evidence for an involvement of CYP2D6 in the metabolism of haloperidol.

KW - CYP2D6

KW - Drug interaction

KW - Fluoxetine

KW - Haloperidol

KW - Negative symptoms

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0030873010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030873010&partnerID=8YFLogxK

M3 - Article

C2 - 9264051

AN - SCOPUS:0030873010

VL - 35

SP - 335

EP - 339

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 4

ER -